China
Africa
Explore chapters and articles related to this topic
Drug Overdoses during Pregnancy
Published in “Bert” Bertis Britt Little, Drugs and Pregnancy, 2022
Overdose of ergotamine during pregnancy was published in a case report of a woman at 35 weeks’ gestation who took 10 tablets of ergotamine tartrate in a suicide gesture. Two hours later uterine contractions began with no relaxation between contractions. Fetal death occurred approximately eight hours after the overdose. Two weeks after the overdose, a macerated stillbirth with no gross abnormality was delivered. Impaired placental perfusion and fetal anoxia associated with ergotamine was speculated to have caused the fetal death (Au et al., 1985). Ergot compound exposure during pregnancy was reviewed for non-overdose use, and reported eight pregnancies exposed during organogenesis. Birth defects reported in these case reports are consistent with increased vascular resistance, spasm, and ischemia (Raymond, 1995). Ergot contaminated animal food results in peripheral gangrene, a result of vascular disruption. A similar etiologic mechanism is suggested for the congenital anomalies observed in cases of non-overdose ergot therapy (Raymond, 1995).
Trigeminal autonomic cephalgias I – cluster headache: diagnosis and treatment
Published in Stephen D. Silberstein, Richard B. Upton, Peter J. Goadsby, Headache in Clinical Practice, 2018
Stephen D. Silberstein, Richard B. Upton, Peter J. Goadsby
Ergotamine tartrate is an agonist at 5-HT1B/1D receptors, as is sumatriptan. It shares many of sumatriptan’s pre-clinical actions.113 Ergotamine tartrate, up to 4mg (in divided doses), is effective and probably poses only a small risk of rebound headache, which may occur in patients with a family history of migraine. Ergotamine is particularly useful in controlling nocturnal attacks when taken at bedtime.11,37,114
E
Published in Anton Sebastian, A Dictionary of the History of Medicine, 2018
Ergotamine [Old French: argot, cock spur; Greek: ammoniakon, resinous gum] First isolated from the fungus Claviceps purpurea by Karl Spiro (1867–1932) and Arthur Stoll (1887–1971) in 1921. Its action on the uterus was studied by Sir John Henry Gaddum (1900–1965) in 1926. Ergotamine tartrate was observed to relieve migraine by Tzanck in 1928. Its therapeutic use in migraine was shown by W.G. Lennox of Americain 1934.
Can Psychedelics Alleviate Symptoms of Cluster Headache and Accompanying Mental Health Problems? A Case Report Involving Hawaiian Baby Woodrose
Published in Journal of Psychoactive Drugs, 2020
Shevaugn Johnson, Quentin C. Black
This case report also highlights a potential link between herpes viruses and cluster headache. The patient’s history of ipsilateral herpetic facial lesions and additional exposure to shingles through her daughter in the weeks preceding the onset of left-sided facial pain suggest such an association. Furthermore, her resolution of cluster headache pain with antiviral treatment points to an etiology of symptoms in her case. While there is not a lot of research reporting on the link between the herpes simplex virus and symptoms of cluster headache, there is some case report evidence in the literature (Joseph and Rose 1985; Sacquegna et al. 1982). It is interesting to note that the authors of one of these case reports also used an ergotamine to manage the client’s symptoms (Joseph and Rose 1985). Ergotamine tartrate is one such agent, first reported as a cluster headache preventive in 1947 (Selby 1983). Furthermore, antiviral properties have been reported in the Hawaiian baby woodrose literature (Joseph et al. 2011), although a 2010 review did not detect any antiviral properties in the Argyreia speciosa seed extracts (Galani, Patel, and Patel 2010).
Cluster headache therapies: pharmacology and mode of action
Published in Expert Review of Clinical Pharmacology, 2020
Jasper Mecklenburg, Margarita Sanchez Del Rio, Uwe Reuter
Ergot derivates can be seen as the precursors of the triptans, as the mode of action is similar. They have widely been replaced by triptans. The mode of action for ergot derivates is believed to be similar to the triptans, as they bind nonspecific to 5-HT receptors. Therefore, their efficacy is probably due to their agonist activity at 5‐HT1B, 5‐HT1D, and 5‐HT1F receptors [85]. Their side effect profiles are secondary to their activity at 5‐HT1A, 5‐HT2A, and dopamine D2 receptors and include severely decreased blood flow, dysphoria, nausea, vomiting, and dysesthesia [86]. In the early 20th century, isolated ergotamine tartrate was one of the first drugs specifically used for primary headaches [87]. The development of dihydroergotamine (DHE) led to a more beneficial side effect profile. Recently the intranasal application of DHE is receiving more attention and is currently studied in migraine [88].
Long-term Ergotamine Derivative Therapy for Migraine Associated with Pachymeningitis and Sixth Cranial Nerve Palsy
Published in Neuro-Ophthalmology, 2019
Dominique Tynan, Kate Ahmad, Mark Thieben
A 57-year-old man presented with a four-day history of horizontal diplopia worse on right lateral gaze and headaches. He described migraines since a teenager and increasing frequency of headaches in the 2 years preceding this presentation that were worse in the morning and when lying down. He had a significant medical history of long-standing reduced visual acuity in his left eye to 6/12 due to congenital toxoplasmosis infection; however, this is was unchanged from previous ophthalmology records. The patient was initially started on Cafergot S 2/100 mg (ergotamine tartrate/caffeine) suppositories 10 years prior and would use 2–3 per month for acute migraines. He changed pharmacist to a compounding pharmacist where he was able to obtain bulk supply of Cafergot suppositories at a significantly cheaper price. Subsequently, he increased his use of ergotamine suppositories to 3 per week in the 3 months prior to his presentation.